Close
Nordic 9Nordic 9

RadForsk (investor - Private Equity)

Norway radforsk.no
See something wrong or missing? Let us know
Offices:Oslo

The Norwegain Radium Hospital Research Foundation (RadForsk) is an early stage evergreen fund dedicated to oncology. RadForsk was founded as an independent foundation in 1986. We invest in oncology, novel therapeutics and diagnostics, with a key focus on immune-oncology.

Average round investment:10.66M USD
Average number per year:1.1
Distribution: 2021 (1)2020 (1)2019 (1)2016 (2)2014 (1) See the entire list
Portfolio companies: Norway OncoinventNorway Zelluna Immunotherapy AsNorway Hubro Therapeutics AS See the entire list
Mostly invests in: Norway Norway (8) Health services (8)
See the entire list

Showing 3 of 8 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

RadForsk mostly invests with:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to RadForsk

Name Criteria
Norway Ferd Capital
79%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Health services, Pharma, Biotech, Software Services
  • Similar business models: B2B
  • Common investees countries: Norway
  • Average number of deals per year: 1.4
  • Active last 12 months: Yes
Norway TeleVenture Management
78%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Health services, Biotech, Software Services
  • Similar business models: B2B
  • Common investees countries: Norway
  • Average number of deals per year: 2.3
  • Active last 12 months: Yes
Sweden Recipharm Venture Fund
76%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Health services, Pharma, Biotech
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Sweden Albonja
76%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Health services, Pharma, Software Services
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Biospring Partners
76%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Health services, Biotech, Software Services
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Spain BBK
76%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Health services, Pharma, Biotech
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
China Zhejiang NHU
76%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Health services, Biotech, Software Services
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
France Siparex
76%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Health services, Biotech, Software Services
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United Kingdom University of Bristol Enterprise Fund
76%
  • Range for average deal size: 5M - 10M USD
  • Similar verticals: Health services, Biotech, Software Services
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Norway Aeternum Capital
76%
  • Range for average deal size: 10M - 20M USD
  • Similar verticals: Health services, Pharma, Software Services
  • Similar business models: B2B
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Top